HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
A team of University at Buffalo researchers has developed a new strontium-loaded scaffold that can be personalized to fit any size dental implant and could help improve healing and tissue attachment ...
INDIANAPOLIS—Researchers from the Indiana Center for Regenerative Medicine and Engineering (ICRME) have identified a new type of cell in the human and mouse body called the vasculogenic fibroblast ...
Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...
Tissue engineering is an interdisciplinary field that combines principles from engineering, biology, and materials science to develop biological substitutes that restore, maintain, or improve tissue ...
FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback